Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.57 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.57 |
| ▸ | CALCRL | Q16602 | 8/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.51 |
| ▸ | CTSS | P25774 | 8/20 | 0.51 |
| ▸ | RAMP1 | O60894 | 3/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2872824 | 0.89 | BRD4 (0.56) | BRD4CREBBPCALCRLCTSSRAMP1 | |
| SCHEMBL12400687 | 0.87 | CHRM4 (0.50) | BRD4CREBBPCALCRLCTSSRAMP1 | |
| SCHEMBL1700379 | 0.87 | CHRM2 (0.50) | BRD4CREBBPCALCRLCHRM2CHRM3 | |
| SCHEMBL14410174 | 0.86 | CALCRL (0.54) | BRD4CREBBPCALCRLCTSSRAMP1 | |
| SCHEMBL14098799 | 0.86 | CHRM4 (0.56) | CALCRLCTSSCHRM4CHRM1 | |
| SCHEMBL14501011 | 0.86 | CALCRL (0.52) | BRD4CREBBPCALCRLCTSSRAMP1 | |
| SCHEMBL13078005 | 0.86 | BRD4 (0.53) | BRD4CREBBPCALCRLCTSSRAMP1 | |
| SCHEMBL5695088 | 0.85 | CALCRL (0.49) | BRD4CREBBPCALCRLCTSSRAMP1 | |
| SCHEMBL5695086 | 0.84 | CHRM4 (0.48) | BRD4CREBBPCALCRLCTSSRAMP1 | |
| SCHEMBL2100919 | 0.83 | BRD4 (0.50) | BRD4CREBBPCALCRLCTSSRAMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3628045-B1 | COMPOUNDS | UNIV SHEFFIELD (GB) | 2024-07-03 | — | — | EP | disclosed |
| US-9663469-B2 | RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663469-B2 | RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160318870-A1 | RORy MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160318870-A1 | RORy MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-11-03 | — | — | US | disclosed |
| US-9212147-B2 | Dihydroxy aromatic heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-15 | — | — | US | disclosed |
| WO-2015035278-A1 | RORγ MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-12 | — | — | WO | disclosed |
| CN-1812982-B | Benzodiazepine CGRP receptor antagonists | MERCK & CO INC | 2010-10-27 | — | — | CN | disclosed |
| US-20100144716-A1 | New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| US-7696209-B2 | CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| US-20090186881-A1 | CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
| US-7528129-B2 | CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-05 | — | — | US | disclosed |
| US-20080280887-A1 | Selected Cgrp-Antagonists, Processes for Preparing Them and Their Use as Pharmaceutical Compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-11-13 | — | — | US | disclosed |
| CN-1812982-A | Benzodiazepine cgrp receptor antagonists | MERCK & CO INC (US) | 2006-08-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186881-A1 | CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | BRD4 2282/4885CREBBP 2225/4885CALCRL 1/4885 |
| US-20160318870-A1 | RORy MODULATORS | RORB, RORC, RORA | BRD4 2572/4885CREBBP 448/4885CALCRL 787/4885 |
| US-20100144716-A1 | New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | BRD4 2232/4885CREBBP 1991/4885CALCRL 1/4885 |
| US-20080280887-A1 | Selected Cgrp-Antagonists, Processes for Preparing Them and Their Use as Pharmaceutical Compositions | CALCRL, CALCR, BDKRB2 | BRD4 1387/4885CREBBP 1986/4885CALCRL 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.